Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Positioning of Current and Emerging Agents for Hepatitis C Virus: Physician and Payer Perspectives on the Prescribing and Reimbursement Landscape in China and South Korea 9/26/2012 \| published by: Decision Resources ... of the population. Peg-IFN (Roche’s Pegasys, Merck’s PegIntron) combined with ribavirin is recommended as first-line therapy by the Chinese HCV Prevention and Treatment Guidelines as well as the NHI of Souths Korea. Although uptake of ... \| read more...	$10,000.00
ChartTrends®: Crohn's Disease (US) 2012 9/26/2012 \| published by: Decision Resources ... audits are completed by 200+ physicians who submit between three and seven audits each. ChartTrends are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. ... \| read more...	$15,000.00
TreatmentTrends®: Rheumatoid Arthritis US (Wave 3) 2012 9/26/2012 \| published by: Decision Resources ... patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. TreatmentTrends® are syndicated report series that provide longitudinal information ... \| read more...	$15,000.00
Niche Markets and Rare Diseases: Squamous Cell Carcinoma of the Head and Neck 9/26/2012 \| published by: Decision Resources ... made with regard to finding biomarkers that can inform treatment choice. Elucidation of human papillomavirus (HPV) status for SCCHN tumors provides prognostic information, but, at this time, treatment is not differentiated between patients with HPV-positive ... \| read more...	$10,000.00
Pulmonary Arterial Hypertension 9/26/2012 \| published by: Decision Resources ... therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets under study, the PAH therapy market is a billion-dollar market and is expected to increase over the 2011-2021 forecast period. ... \| read more...	$15,000.00
Zytiga and the Crowded Late-Stage Pipeline: How Will U.S. Payer and Prescriber Attitudes and Decisions Shape the Prostate Cancer Market? 9/26/2012 \| published by: Decision Resources ... Provenge (sipuleucel-T) was approved for asymptomatic or minimally symptomatic chemotherapy-naive mCRPC. In second- and subsequent-line mCRPC, three novel agents have been approved for patients who have received prior docetaxel: Sanofi’s Jevtana (cabazitaxel) in June 2010, ... \| read more...	$10,000.00
TreatmentTrends®: Anemia Managers 2012 9/24/2012 \| published by: Decision Resources ... business aspects of anemia management in the dialysis setting. Anemia Managers (AMs) are an important part of the care team for dialysis patients. Typically, AMs are responsible for the “clinical” side of anemia management including ... \| read more...	$15,000.00
TreatmentTrends®: Age-Related Macular Degeneration (US) 2012 9/20/2012 \| published by: Decision Resources ... from the perspective of retinal specialists and general ophthalmologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use ... \| read more...	$15,000.00
Biosimilars Advisory Service: Physician Perspectives on Pegylated IFN-a and TNF-a Inhibitors in Immune and Infectious Disease 9/19/2012 \| published by: Decision Resources ... primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business. ... \| read more...	$10,000.00
Cybercitizen Health® U.S. 2012 9/19/2012 \| published by: Decision Resources ... The study is fielded annually in Q3 among more than 8,700 U.S. adults online and on the phone. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$10,000.00
Spain: Market Access Tracker 9/18/2012 \| published by: Decision Resources ... uptake of new drugs than the other major European pharmaceutical markets. However, the Spanish market presents some significant challenges for pharmaceutical companies: prices are among the lowest in Europe, and the Spanish government has imposed ... \| read more...	$4,000.00
TreatmentTrends®: Multiple Sclerosis (US) Q3 2012 9/14/2012 \| published by: Decision Resources ... the perspective of neurologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate ... \| read more...	$15,000.00
LaunchTrends®: Peginesatide (Omontys)(Anemia ESRD)(Wave 2) 2012 9/14/2012 \| published by: Decision Resources ... room for a fourth product? LaunchTrends® are a series of four syndicated reports that track the trial, adoption, and usage during a Omontys’ initial market introduction. Fielding occurs at one, three, six and twelve months ... \| read more...	$15,000.00
Positioning of Current Biologics for Crohn’s Disease and Ulcerative Colitis: Physician and Payer Insight into Market Access Drivers in China and South Korea 9/12/2012 \| published by: Decision Resources ... of biologics has become more generous in recent years, as evidence for the efficacy of the TNF-a inhibitors has accumulated. In China, Remicade, the first biological agent approved for CD has been added to several ... \| read more...	$10,000.00
ChartTrends®: Rheumatoid Arthritis (US) 2012 9/11/2012 \| published by: Decision Resources ... what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host ... \| read more...	$15,000.00
Oncology Patient Flow Model: Hepatocellular Carcinoma 9/10/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
Prostate Cancer in Russia 9/10/2012 \| published by: Decision Resources ... growth will be substantially higher than in the major markets. Changes in medical practice and a growing incident population offer significant opportunity to multinational companies (MNCs) with emerging therapies in this indication. In this report, ... \| read more...	$15,000.00
Malignant Melanoma 9/5/2012 \| published by: Decision Resources ... BRAF inhibitor, is the first targeted therapy approved for MM with a companion diagnostic test. Its launch has driven segmentation of the unresectable and metastatic MM population by BRAF mutational status. The anticipated approval of ... \| read more...	$15,000.00
Oncology Patient Flow Model: Malignant Melanoma 9/5/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
South Korea: Market Access Tracker 8/30/2012 \| published by: Decision Resources ... and South Korea. Timely analysis of key events, regular webinar update presentations, and access to our team of experts will equip biopharmaceutical companies with the insight needed to evaluate the implications of the latest changes ... \| read more...	$4,000.00
ChartTrends®: Multiple Sclerosis (EU) 2012 8/29/2012 \| published by: Decision Resources ... patient audits are completed by 225+ neurologists who submit between four and seven audits each. Respondents are limited to one patient per disease-modifying agent (DMA) brand (Avonex, Betaferon, Copaxone, Extavia, Gilenya, Rebif and Tysabri). At ... \| read more...	$15,000.00
LaunchTrends®: Dificid (Wave 4) 2012 8/28/2012 \| published by: Decision Resources ... 4 track the introduction of Dificid over the months following the July 2011 launch. Reports are based on data collected at pre-launch, three months, six months and twelve months post-Dificid launch. LaunchTrends is a syndicated ... \| read more...	$15,000.00
How Will Reimbursement Decisions for Novel Biologics and Biosimilars Impact Prescribing in the Dynamic Markets for Crohn’s Disease and Ulcerative Colitis? 8/28/2012 \| published by: Decision Resources ... marketed biologic. In both CD and UC, Janssen Biotech’s Remicade (infliximab) continues to dominate the U.S. market and stand as the therapy to beat for agents positioned in the segment of the market for patients ... \| read more...	$10,000.00
TreatmentTrends®: Bone and Mineral Metabolism (Belgium & The Netherlands) 2012 8/27/2012 \| published by: Decision Resources ... management of bone and mineral metabolism and the report will cover practice dynamics, key product current use and future use projections, and perceived product advantages and disadvantages. Please note, the PDF e-mail from publisher version ... \| read more...	$15,000.00
Hospital-Treated Gram-Negative Infections 8/23/2012 \| published by: Decision Resources ... MRSA; however, as the MRSA market becomes saturated with effective agents and as multidrug resistance in key gram-negative pathogens ( Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae) continues to rise, the GNI market ... \| read more...	$15,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >